Analyzing Seaport Therapeutics (SPTX) and The Competition

Seaport Therapeutics (NASDAQ:SPTX) is one of 907 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Seaport Therapeutics to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, valuation, risk, earnings and profitability.

Earnings & Valuation

This table compares Seaport Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seaport Therapeutics	N/A	-$74.88 million	-1.99
Seaport Therapeutics Competitors	$3.48 billion	$3.12 billion	539.25

Seaport Therapeutics’ rivals have higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for Seaport Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2	3	5	0	2.30
Seaport Therapeutics Competitors	7675	13635	25504	989	2.41

Seaport Therapeutics presently has a consensus target price of $38.40, indicating a potential upside of 58.94%. As a group, “Pharmaceuticals” companies have a potential upside of 28.16%. Given Seaport Therapeutics’ higher possible upside, research analysts plainly believe Seaport Therapeutics is more favorable than its rivals.

Profitability

This table compares Seaport Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Seaport Therapeutics Competitors	-2,313.88%	-224.78%	-17.83%

Institutional & Insider Ownership

32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 13.9% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Seaport Therapeutics rivals beat Seaport Therapeutics on 8 of the 12 factors compared.

About Seaport Therapeutics

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.